Posted by Michael Wonder on 25 Sep 2017
Roche receives European approval for Actemra/RoActemra in giant cell arteritis
22 September 2017 - The approval was based on the outcome of the phase III GiACTA study.
Roche announced today that the European Commission has approved Actemra/RoActemra (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition.
Actemra/RoActemra is the first therapy approved for the treatment of GCA in Europe.
